Home / Resource Library / Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma

Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma

Updated results of a phase II trial of acalabrutinib for treatment of relapsed mantle cell lymphoma.